RxDoctor Payments Data

George Gray, MD

Family Medicine · Vero Beach, FLNPI 1952494015

Payments from drug & device makers

$10,599in general payments, 2019–2025

Across 539 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Boehringer Ingelheim$931
  • GSK$899
  • Lilly USA, LLC$864
  • Esperion Therapeutics, Inc.$497
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$10,30397%
  • Education$2973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,599 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$190,450
Medicare patients
420
Services billed
1,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$88,583
JardianceEmpagliflozin39$54,575
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$48,247
MounjaroTirzepatide38$45,116
OzempicSemaglutide36$39,830
JanuviaSitagliptin Phosphate29$33,548
GemtesaVibegron14$16,863
RybelsusSemaglutide12$15,267
MyrbetriqMirabegron18$13,243
Omeprazole365$6,903
Ezetimibe425$6,281
Desvenlafaxine Succinate ErDesvenlafaxine Succinate67$6,059
Combivent RespimatIpratropium/Albuterol Sulfate12$5,894
Atorvastatin Calcium568$5,211
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine113$4,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$458$88,58383 claims
Boehringer IngelheimJardiance, Combivent Respimat$931$60,47051 claims
Novo NordiskOzempic, Rybelsus$1,206$55,09748 claims
GSKTrelegy Ellipta$899$48,24738 claims
Lilly USA, LLCMounjaro, Olanzapine$864$47,502138 claims
Sumitomo Pharma America, Inc.Gemtesa$166$16,86314 claims
Astellas Pharma US IncMyrbetriq$392$13,24318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →